STOCK TITAN

UCB SA - UCBJY STOCK NEWS

Welcome to our dedicated page for UCB SA news (Ticker: UCBJY), a resource for investors and traders seeking the latest updates and insights on UCB SA stock.

UCB SA UNSP/ADR (UCBJY) is a global biopharmaceutical company focused on developing innovative medicines for immune system and central nervous system diseases. Recent achievements include 48-week post-hoc analyses of pooled Phase 3 data from the BE HEARD I and BE HEARD II studies for hidradenitis suppurativa patients, showing clinically meaningful improvements in skin pain and draining tunnels with BIMZELX treatment. The company is actively pursuing regulatory applications globally for the approval of BIMZELX.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.19%
Tags
-
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.4%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.61%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.5%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.82%
Tags
partnership
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.25%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.48%
Tags
conferences clinical trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.05%
Tags
none

FAQ

What is UCB SA UNSP/ADR known for?

UCB SA UNSP/ADR, with the symbol UCBJY, is a renowned global biopharmaceutical company dedicated to developing innovative medicines for patients with severe immune system and central nervous system diseases.

What are the recent achievements of UCBJY?

The company recently shared 48-week post-hoc analyses of pooled Phase 3 data from the BE HEARD I and BE HEARD II studies, showcasing the impact of BIMZELX on hidradenitis suppurativa patients' skin pain and draining tunnels.

What regulatory milestones have UCBJY achieved recently?

UCB has announced that the FDA accepted a supplemental Biologics License Application (sBLA) for BIMZELX for the treatment of moderate-to-severe hidradenitis suppurativa (HS), along with a second sBLA for BIMZELX 2mL device presentations.

What is the status of BIMZELX approval in the U.S.?

BIMZELX is currently approved in the U.S. for moderate-to-severe plaque psoriasis in adults and is under regulatory review for moderate-to-severe HS, psoriatic arthritis, non-radiographic axial spondyloarthritis, and ankylosing spondylitis.

What are the key secondary endpoints of the BE HEARD I and BE HEARD II studies?

The primary endpoint of both trials was HiSCR50 at Week 16, with a key secondary endpoint being HiSCR75 at Week 16, defined as a 50 or 75 percent reduction from baseline in total abscess and inflammatory nodule count.

UCB SA

OTC:UCBJY

UCBJY Rankings

UCBJY Stock Data

28.14B
119.66M
0%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
Anderlecht